European Journal of Cancer

Article	Citations
Editorial Board	449
Standardization of viability assays and high-content live-cell imaging protocols for large-scale drug testing in prostate cancer PDX-derived organoids	316
Corrigendum to ‘Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Jour	218
Editorial Board	193
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	182
Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	175
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	162
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma	158
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study	140
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents	139
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need	135
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment	124
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study	124
A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy	119
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas	114
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases	104
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica	101
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1	95
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins	94
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story	91
250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia	89
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC	84
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types	82
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue	81
300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers	80

417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	77
441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity	76
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development	75
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer	75
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis	73
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	72
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	71
Macular type of primary cutaneous B-cell lymphoma: extension of the clinical and histopathological patterns	70
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	67
The role of a patient with breast cancer in a multidisciplinary team – from making a decision to changing the treatment option	66
Spectrum of dermo-epidermic cutaneous gamma-delta lymphomas from a single center: clinical and phenotypic analysis of an heterogenous lymphoproliferative disorder	66
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	65
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	65
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	65
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	64
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	63
Discovery of Essential microRNA in Prostate Cancer Cells	63
Non-clinical identification and characterization of KRAS G12D inhibitors	62
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	62
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	61
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas	60
T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples	60
Impact of establishing a genetic clinic in conjunction with clinical practice in India	60
Preoperative accelerated partial breast irradiation in locally recurrent breast cancer patients	58
The Punjab breast cancer AI-digital project: Implementing Artificial Intelligence-based triaging at scale for population-level screening of breast cancer	57
Contrast-enhanced mammography (CEM) with magnetic tracer as an alternative to MRI	56
Interobserver variation in the assessment of HER2 low expression in breast cancer: can we improve by adjusting criteria? An international interobserver study	54
Clinical and Experimental investigation of AKT1/2/3 isoforms indicated non-redundant isoform specific role in driving stemness and Cisplatin resistance in TNBCs	54
Impact of an Online Educational Activity on Oncologists’ Knowledge and Competence Regrading the Optimal Use of Adjuvant Treatment in Breast Cancer	54
SNP rs10748643 within the promoter region of ENTPD1 (the gene encoding CD39) has no prognostic value in Sézary patients	53
The Sponsor Acknowledgment and Introduction	53
An update on health-related quality of life from the PROCLIPI study	53
Efficiency of textile photodynamic therapy for mycosis fungoides	53
Experience of a supra-regional cutaneous lymphoma centre during the COVID-19 pandemic	53
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies	52
Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer	52
Neoadjuvant treatment for breast cancer patients in a Venezuelan breast center. Pathologic complete response: is it worth it?	52
Triple negative breast cancers: Rising menace in the developing world and treatment challenges	52
Home based care for terminal cancer patients: study from rural part of India	51
Local recurrence of breast cancer after mastectomy. Impact of residual tissue in cancer follow-up	51
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy	50
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer	50
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma	50
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System	49
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer	49
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	49
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS	49
Perspectives on the role of “-Omics” in predicting response to immunotherapy	49
Immunotherapy for brain metastases and primary brain tumors	48
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)	48

10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis	48
Recent advances and future strategies in first-line treatment of ES-SCLC	47
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 tr	47
New drugs and options can enhance patient outcomes: But can they also erode them?	46
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib	46
Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials	46
Cancer and immunotherapy: a role for microbiota composition	45
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis	45
Gene expression-based prediction of pazopanib efficacy in sarcoma	44
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants	44
Early versus late response to PD-1-based immunotherapy in metastatic melanoma	44
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry	44
Troponin increase during immunotherapy: Not always myocarditis	44
Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity	44
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands	43
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters	43
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS	43
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	43
Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials	43
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01	43
Unexpectedly high seroprevalance of Kaposi's sarcoma-associated herpesvirus (HHV-8) in patients with stage IV melanoma	43
Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities	42
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies	42
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer	42
Life-threatening skin reaction with Enfortumab Vedotin: Six cases	42
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling,	42
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizum	42
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	42
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study	41
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice	41
Granulomatous slack skin: clinical retrospective study of 8 cases of the Cutaneous Lymphoma French Study Group	40
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations	40
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma	40
Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck	40
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma	40
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life	40
DNA methylation markers in the detection of hepatocellular carcinoma	40
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer	39
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma	39
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients	39
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patien	39
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164	39
Letter Re: Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS	38
Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy	38
Patient-led follow-up after curative colorectal cancer surgery: The primary outcome analysis of the prospective, multicentre FUTURE-primary implementation study	38
Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: Prognostic scores as a way forward	38
Ocular, meningeal and cerebral involvement of mycosis fungoides associated with an immunophenotypic switch from CD4+ to CD8+	37
First xenograft and cell line of primary cutaneous diffuse large B-cell lymphoma, leg type	37
Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues	37
Characteristics and clinical outcomes of breast cancer patients under different modalities of breast-conserving surgery and lymph node management in China	36
A multidisciplinary approach to the enhancement of quality of life of breast cancer patients in the South-west, Nigeria	36
Photodynamic therapy for the treatment of primary cutaneous B-cell marginal zone lymphoma: a series of 4 patients	36
PD1 regulates T cell exhaustion phenotypes and disease aggressiveness in CTCL	36
Real-life evaluation of efficacy and tolerability of chlormethine gel in Italian centers	36
Evaluation of the role of different cell populations in mycosis fungoides microenvironment as a tool for biomarker identification for disease progression and individualized therapy	35
Initial experience with targeted axillary dissection (TAD) guided by ultrasound in early-stage node positive breast cancer patients undergoing upfront surgery	35
Targeted axillary dissection or sentinel node biopsy after neo-adjuvant treatment in clinically node positive patients – the West of Scotland experience	35
Triple-negative breast cancer cells that survive ionizing radiation exhibit an Axl-dependent aggressive radioresistant phenotype	35
High PD1 expression H score is associated with Sézary diagnosis: study of 91 patients with erythroderma	35
Contrast Enhanced Mammography in Breast Cancer Surveillance	35
Racial disparity and time to treatment initiation effects on survival differences in breast cancer: a DAGs-based review protocol for a systematic review of cohort studies	35
Contrast enhanced mammography in further assessment of screen-detected breast cancer	35
Peripheral blood neutrophil/lymphocyte ratio as a prognostic factor in triple negative breast cancer	35
Mode of Recurrence/ Metastasis Detection in Breast cancer survivors	34
Characterisation of adaptive responses of cancer cells to oxaliplatin by analysis of leading edge genes from genes set enrichment analysis	34
Title Page	34
Editorial Board	34
HX301, a potent CSF1R inhibitor, suppresses tumor associated M2 macrophage (TAM), enhancing tumor immunity and causing transit tumor inhibition in syngeneic EMT-6 tumors	34
Efficacy and safety of abemaciclib in the treatment of HR+ HER2-advanced breast cancer: real world data	34
The microbiome of patients with breast cancer; observational study on the microbiome composition of breast cancer patients and the effects of chemotherapy treatment on the microbiome	34
Primary cutaneous follicle center lymphoma with secondary systemic evolution	34
Is there microbial dysbiosis in CTCL? A pilot study	33
Regulation of oncogenic transcription and tumor growth in pediatric cancers by the CDK9 inhibitor KB-0742	33
Multimodal therapy with bexarotene and extracorporeal photopheresis for T-cell cutaneous lymphomas: real-life experiences in Argentina	32
MYC inhibition by Omomyc unveils a prognostic gene signature in Melanoma	32
A novel computational pathology approach for identifying gene signatures prognostic of disease-free survival for papillary thyroid carcinomas	32
Loss of RHOA impairs lenalidomide antitumor activity in mantle cell lymphoma	32
Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: interim analysis of the German non-interventional MINT study	32
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors	32
A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study	32

Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1	32
Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study	31
Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis	31
Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization – Implications in treatment outcomes	31
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics	31
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas	31
Placing the patient at the heart of discovery science	31
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients	31
An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations	31
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients	31
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies	31
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer	31
Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial	31
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years	30
Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation	30
Nivolumab induces long-term remission in a patient with fusariosis	30
Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas	30
Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience	30
Temporal changes in survival among adult patients with acute lymphoblastic leukaemia diagnosed in the period 1998-2020 – A Danish nationwide population-based cohort study	30
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours	30
444 (PB432): First-in-human phase 1 study of RGT-264, a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor in patients (pts) with advanced solid tumors	29
294 (PB282): Suppression of Glioblastoma Progression by FDA-Approved Central Nervous System-Accumulating Drugs via Autophagy Modulation and ER Stress-Induced Apoptosis	29
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months	29
121 (PB109): TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study	29
237 (PB225): Targeting NOS sensitizes the NRAS-mutant melanomas to MEK inhibition and induces Immunogenic Cell Death	29
146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies	29
443 (PB431): A Sub Analysis of Clinical Study of Tomaralimab, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylat	28
43 (PB031): MBT-C101, a first-in-class, selective, and potent HSP90 chaperonemediated degrader of PI3Ka	28
299 (PB287): Lomitapide enhances cytotoxic effects of temozolomide in chemoresistant glioblastoma	28
100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild	28
158 (PB146): Immune Monitoring in Preclinical Tumor Mouse Models Using Spectral Analyzer Technology	28
26 (PB014): Development of Tumour-specific CD146 CAR-T Cells for Targeted Cancer Immunotherapy of Solid Tumours	28
344 (PB332): Systematic assessment of ALC1 depletion as a therapeutic approach in homologous recombination deficient cells	28
Systematic nutritional screening and assessment in older patients: Rationale for its integration into oncology practice	28
Editorial Board	28
Peer Review Policy for the European Journal of Cancer (EJC)	27
A-186 Molecular Insights into Primary Cutaneous CD30+ T-cell Lymphoproliferative Disorders: Wnt/Beta-Catenin Pathway Activation and Prognostic Role of TP53 mutations?	27
Computerizing the first step of the two-step algorithm in dermoscopy: A convolutional neural network for differentiating melanocytic from non-melanocytic skin lesions	27
ERBB2 mRNA expression in HER2-low breast cancer	27
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study	27
A-206 4 cases of pediatrics mycosis fungoides revealed by recalcitrant psoriatic palmoplantar keratoderma	27
A-170 Is there microbial dysbiosis in CTCL? A pilot study	27
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial	27
A-200 Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study	27
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer	27
A-153 Primary cutaneous T-cell lymphoma not otherwise specified (NOS) uncovering a novel RAB27A variant in Griscelli syndrome type 2	27
Reliability of patient-reported toxicities during adjuvant chemotherapy	27
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study	27
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA	27
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience	26
Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC	26
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy	26
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial	26
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer	26
Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience	26
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)	26
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases	26
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours	26
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme	26
A machine learning tool for identifying non-metastatic colorectal cancer in primary care	26
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment	26
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)	26
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered dise	26
HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study	25
Norwegian general population normative data for the European Organization for Research and Treatment of Cancer questionnaires: the Quality of Life Questionnaire-Core 30, the Sexual Health Questionnair	25
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients	25
Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)	25
Quality of life in cutaneous lymphoma varies by lymphoma type	25
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study	25
Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis	25
Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis	25
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial	25
Intraoperative ultrasound is accurate for guiding breast conservative surgery in non-palpable ductal carcinoma in situ of the breast	24
Editorial Board	24
Interhospital variations in diagnostic work-up following recall at biennial screening mammography – a population-based study	24
The relationship among bowel FDG-PET uptake, pathological complete response, and eating habits in breast cancer patients undergoing neoadjuvant chemotherapy	24
OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis	24
Eliminating the Immunotoxicity of Interleukin-12 through Protease-Sensitive Masking	24
Nipple-sparing mastectomy with primary breast reconstruction: Breast cancer local recurrence according to molecular subtype	24
Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles	24
The role of the certified surgeon-oncologist in improving the diagnosis and operative treatment of patients with breast tumors	24
Response to letter entitled: Re: Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study	24
MaThAI: A MultiModal imaging combining Mammography and Thermalytix for better prioritization of mammography scans to detect early malignancies	24
Liquid biopsy assessment in primary cutaneous diffuse large B-Cell lymphoma- leg type	24
Discovery of I-0436650, a potent and selective SHP2 allosteric inhibitor for the treatment of RAS driven solid tumors	24
Coverage and Socio-economic inequalities in breast cancer screening in Low- and Middle-Income Countries: Analysis of Demographic and Health Surveys between 2010 and 2019	24
Exposure-response relation in metastatic colorectal cancer organoids after high-dose short-term tyrosine kinase inhibitor exposure	24
One-step nucleic acid amplification assay in palpable and non-palpable breast tumours	24
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lu	24
Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study	24
Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients	23
Adherence to clinical practice guidelines: a population-based study of socio-economic inequalities in breast cancer	23
NUC-3373 is a potent TS inhibitor and induces DNA damage in NSCLC cancer cells regardless of histological subtype	23
Real-world outcomes and tolerability of mogamulizumab monotherapy and multimodality therapy for cutaneous T-cell lymphoma: results from a multicenter retrospective cohort study	23
Immune cell profiling and regulatory proteins in MF lesions	23